Close

Canaccord Genuity Reiterates a 'Buy' on Momenta Pharmaceuticals (MNTA); Generic Copaxone Suit: Strong Defendant Opening Arguments on Noninfringement

September 8, 2011 8:31 AM EDT Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target of $27.00.

Canaccord analyst, Ritu Baral, said, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login